Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the anticipated market size of the cardiotonic agents industry over the next few years?
The cardiotonic agents market size has grown rapidly in recent years. It will grow from $2.78 billion in 2024 to $3.14 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing prevalence of heart failure, a growing geriatric population, rising incidence of coronary artery disease, increasing adoption of sedentary lifestyles, and a growing burden of hypertension and diabetes.
The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to rising cardiovascular mortality rates, rising clinical trials focusing on improved cardiotonic formulations, rising public-private partnerships in cardiovascular drug development, growing hospital admissions due to cardiac complications, and growing demand for personalized cardiovascular medicine. Major trends in the forecast period include developing peptide-based cardiotonic agents, developing dual-mechanism drugs, integrating pharmacogenomics, innovating injectable depot formulations, and innovating combination therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp
What emerging drivers are expected to shape the future of the cardiotonic agents market?
The rise in prevalence of cardiovascular diseases is expected to propel the growth of the cardiotonic agents market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders that affect the heart and blood vessels, including conditions such as coronary artery disease, heart failure, arrhythmias, and stroke. The rise in cardiovascular diseases is primarily due to unhealthy diets high in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents improve the efficiency and contraction strength of the heart muscle, thereby supporting better blood circulation and reducing symptoms in various cardiovascular diseases. For instance, in December 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, doctor-certified deaths due to coronary heart disease (CHD) in Australia increased from 14,100 in 2021 to 14,900 in 2022. Therefore, the rise in prevalence of cardiovascular diseases is driving the growth of the cardiotonic agents market.
What emerging segments are shaping the future landscape of the cardiotonic agents industry?
The cardiotonic agents market covered in this report is segmented –
1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Dosage Form: Tablet, Solution, Other Dosage Forms
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report
What are the top market trends driving innovation in the cardiotonic agents industry?
Major companies operating in the cardiotonic agents market are focusing on developing innovative products, such as short-term inotropic drugs, to enhance cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are medications used to temporarily enhance the heart’s ability to contract, thereby improving cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is used for short-term inotropic support in adults experiencing cardiac decompensation due to reduced heart contractility, commonly caused by heart disease or following cardiac surgery. It works by stimulating beta-1 receptors, which enhances heart muscle contractility and cardiac output with a rapid onset (1–2 minutes). The injection is administered intravenously and is typically given in a hospital setting with close monitoring.
How are key players in the cardiotonic agents market strengthening their market position?
Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.
Which geographic areas are contributing significantly to the growth of the cardiotonic agents sector?
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Cardiotonic Agents Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp
Need Customized Data On Cardiotonic Agents Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
